Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome

University of Colorado, Denver

Overview

The metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. The purpose of this study is to find out if the medication, rosiglitazone, influences levels of fat cell proteins and alters insulin resistance in nondiabetic persons with the metabolic syndrome. This is an early step to see if a medication, such as rosiglitazone, will be beneficial in people who have the metabolic syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Metabolic Syndrome Insulin Resistance

Interventions

RosiglitazoneDRUG

Eligibility

Sex: ALLMin age: 30 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Nondiabetic subjects with an NCEP/ATP III diagnosis of the metabolic syndrome Exclusion Criteria: * Statin Medications, liver disease, cardiovascular disease, heart failure, diabetes, chronic kidney disease,

Locations (1)

University of Colorado at Denver and Health Sciences Center General Clinical Research Center

Denver, Colorado, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.